GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Other Current Assets

Gene Biotherapeutics (Gene Biotherapeutics) Other Current Assets : $0.03 Mil (As of Dec. 2020)


View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Other Current Assets?

Gene Biotherapeutics's other current assets for the quarter that ended in Dec. 2020 was $0.03 Mil.

Gene Biotherapeutics's quarterly other current assets declined from Jun. 2020 ($0.02 Mil) to Sep. 2020 ($0.02 Mil) but then increased from Sep. 2020 ($0.02 Mil) to Dec. 2020 ($0.03Mil).

Gene Biotherapeutics's annual other current assets increased from Dec. 2018 ($0.02 Mil) to Dec. 2019 ($0.03 Mil) declined from Dec. 2019 ($0.03 Mil) to Dec. 2020 ($0.03 Mil).


Gene Biotherapeutics Other Current Assets Historical Data

The historical data trend for Gene Biotherapeutics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Other Current Assets Chart

Gene Biotherapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.03 0.02 0.03 0.03

Gene Biotherapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.11 0.02 0.02 0.03

Gene Biotherapeutics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Gene Biotherapeutics Other Current Assets Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Executives
Andrew M Leitch director 6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison director C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy officer: Chief Financial Officer
Ronald I Simon other: Former Director 485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten director, officer: PRESIDENT and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines